CORE-004: CLINICAL TREATMENT UNIT AND CLINICAL TRIALS PROCESSING LABORATORY (CTU/CTPL SR) PROJECT SUMMARY / ABSTRACT The mission of the OSUCCC Clinical Treatment Unit and Clinical Trials Processing Laboratory Shared Resource (CTU/CTPL SR) is to advance the quality and efficiency of early phase clinical translational research. The CTU/CTPL SR, directed by Dr. Larry Schaaf, is composed of two different units that are intimately related: the Clinical Treatment Unit (CTU) and the Clinical Trials Processing Laboratory (CTPL). The CTU/CTPL was established in 2004 to support and expand our ability to conduct early phase trials (CTU) and the supports the processing of biospecimens for any CTO-managed trial (CTPL). It has particular expertise for, and is strategically located, supporting the OSUCCC clinical trials, especially early phase trials; 42% of the CTPL activities are for early phase trials conducted in the CTU. The CTU/CTPL was formally reviewed as a new shared resource in 2009, where funding was only requested for the CTPL. (The OSUCCC funded the CTU from institutional support, and will continue to do so). The CTPL enhances the quality of research by providing dedicated staff for high volume procurement, processing, storage, delivery, and shipment of research biospecimens critical to the correlative studies component of OSUCCC clinical trials. Highly trained staff in the CTU/CTPL SR work closely with the Clinical Trials Office (CTO) and other shared resources to provide protocol review and feasibility assessment, specimen kit assembly and distribution of specimens to internal and external research laboratories.
The Specific Aims of the CTU/CTPL are: 1) to provide a stable, reliable, and cost-effective, state-of-the art unit for conducting early phase clinical trials requiring intense monitoring and/or complex correlative specimen collection; and, 2) to provide high quality, high volume specimen processing, short-term storage and distribution of biospecimens collected as correlative components of phase I, II and III translational clinical trials. During this previous grant cycle, the CTU has supported 142 protocols involving 1,354 patients with 14,490 patient visits, and the CTPL has procured and processed 82,454 research specimens on 381 protocols. During the past year, the CTU has supported 71 protocols involving 363 patients with 2,995 patient visits and the CTPL has procured and/or processed 17,875 research specimens on 216 protocols. During this time, 45 OSUCCC members, representing all five OSUCCC research programs, and accounting for 72% of the overall CTU/CTPL SR usage, have utilized the CTU/CTPL SR. The remainder of the usage was by clinical oncology faculty who work under the direct supervision of OSUCCC members. The CTPL has contributed to over 79 publications over the last five year grant period (16 with an impact factor > 10). The CTPL will continue to enhance the quality of clinical translational research conducted at the OSUCCC by providing improved efficiency, enhanced compliance, and cost-effective centralized support of early phase correlative studies. Expansion capacity is available given the additional space obtained by moving the CTU/CTPL to the new James Cancer Hospital, and the CTPL are considering expansion to additional clinical sites. The CTPL leverages extensive institutional support, and seeks only 18.9% support from CCSG funds. The Clinical Treatment Unit and Clinical Trials Processing Laboratory is part of the Clinical Grouping.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-44
Application #
9843862
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
44
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Yadav, Marshleen; Song, Feifei; Huang, Jason et al. (2018) Ocimum flavone Orientin as a countermeasure for thrombocytopenia. Sci Rep 8:5075
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
White, Brian S; Lanc, Irena; O'Neal, Julie et al. (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35
Owen, Dwight; Chaft, Jamie E (2018) Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis 10:S404-S411
O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C et al. (2018) Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol 4:712-716
Guo, Sijin; Piao, Xijun; Li, Hui et al. (2018) Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor. Methods 143:121-133
Sadowski, Abbey R; Gardner, Heather L; Borgatti, Antonella et al. (2018) Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 14:250
Barredo, Julio C; Hastings, Caroline; Lu, Xiamin et al. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 65:e26928
Kim, So-Youn; Nair, Devi M; Romero, Megan et al. (2018) Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ :
Farquhar, Neil; Thornton, Sophie; Coupland, Sarah E et al. (2018) Patterns of BAP1 protein expression provide insights into prognostic significance and the biology of uveal melanoma. J Pathol Clin Res 4:26-38

Showing the most recent 10 out of 2602 publications